FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2252994773> ?p ?o ?g. }

• W2252994773 endingPage "1049" @default.
• W2252994773 startingPage "1041" @default.
• W2252994773 abstract "Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA remains controversial in LRT with tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids.The Organ Procurement and Transplantation Network registry was studied for patients receiving LRT from 2000 to 2012 maintained on TAC/MPA at discharge (n=36,153) to compare effectiveness of IL2-RA to other induction options. The cohort was initially divided into two groups based on use of maintenance steroid at time of hospital discharge: steroid (n=25,996) versus no-steroid (n=10,157). Each group was further stratified into three categories according to commonly used antibody induction approach: IL2-RA, rabbit anti-thymocyte globulin (r-ATG), and no-induction in the steroid group versus IL2-RA, r-ATG and alemtuzumab in the no-steroid group. The main outcomes were the risk of acute rejection at 1 year and overall allograft failure (graft failure or death) post-transplantation through the end of follow-up. Propensity score-weighted regression analysis was used to minimize selection bias due to non-random assignment of induction therapies.Multivariable logistic and Cox analysis adjusted for propensity score showed that outcomes in the steroid group were similar between no-induction (odds ratio [OR], 0.96; 95% confidence interval [95% CI], 0.86 to 1.08 for acute rejection; and hazard ratio [HR], 0.99; 95% CI, 0.90 to 1.08 for overall allograft failure) and IL2-RA categories. In the no-steroid group, odds of acute rejection with r-ATG (OR, 0.73; 95% CI, 0.59 to 0.90) and alemtuzumab (OR, 0.53; 95% CI, 0.42 to 0.67) were lower; however, overall allograft failure risk was higher with alemtuzumab (HR, 1.27; 95% CI, 1.03 to 1.56) but not with r-ATG (HR, 1.19; 95% CI, 0.97 to 1.45), compared with IL2-RA induction.Compared with no-induction therapy, IL2-RA induction was not associated with better outcomes when TAC/MPA/steroids were used in LRT recipients. r-ATG appears to be an acceptable and possibly the preferred induction alternative for IL2-RA in steroid-avoidance protocols." @default.
• W2252994773 created "2016-06-24" @default.
• W2252994773 creator A5016874418 @default.
• W2252994773 creator A5022620756 @default.
• W2252994773 creator A5030683638 @default.
• W2252994773 creator A5038631687 @default.
• W2252994773 creator A5046182499 @default.
• W2252994773 creator A5056261742 @default.
• W2252994773 creator A5064511107 @default.
• W2252994773 creator A5065873172 @default.
• W2252994773 creator A5067822524 @default.
• W2252994773 creator A5077167854 @default.
• W2252994773 creator A5077759641 @default.
• W2252994773 creator A5081469801 @default.
• W2252994773 creator A5084636437 @default.
• W2252994773 date "2015-06-01" @default.
• W2252994773 modified "2023-10-17" @default.
• W2252994773 title "Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance" @default.
• W2252994773 cites W1553403936 @default.
• W2252994773 cites W1581327084 @default.
• W2252994773 cites W1665088674 @default.
• W2252994773 cites W166739738 @default.
• W2252994773 cites W1906296259 @default.
• W2252994773 cites W1933130760 @default.
• W2252994773 cites W1934366345 @default.
• W2252994773 cites W1938418234 @default.
• W2252994773 cites W1962392014 @default.
• W2252994773 cites W1990443201 @default.
• W2252994773 cites W1995261519 @default.
• W2252994773 cites W1996351770 @default.
• W2252994773 cites W2015236177 @default.
• W2252994773 cites W2022076910 @default.
• W2252994773 cites W2026860062 @default.
• W2252994773 cites W2035061164 @default.
• W2252994773 cites W2042463878 @default.
• W2252994773 cites W2043363204 @default.
• W2252994773 cites W2045752685 @default.
• W2252994773 cites W2053413923 @default.
• W2252994773 cites W2062545746 @default.
• W2252994773 cites W2063759059 @default.
• W2252994773 cites W2068847188 @default.
• W2252994773 cites W2078939327 @default.
• W2252994773 cites W2087317980 @default.
• W2252994773 cites W2093399787 @default.
• W2252994773 cites W2095107584 @default.
• W2252994773 cites W2121690051 @default.
• W2252994773 cites W2122004550 @default.
• W2252994773 cites W2122532950 @default.
• W2252994773 cites W2127536951 @default.
• W2252994773 cites W2142288396 @default.
• W2252994773 cites W2151417740 @default.
• W2252994773 cites W2315162536 @default.
• W2252994773 cites W4211117577 @default.
• W2252994773 cites W4251063858 @default.
• W2252994773 doi "https://doi.org/10.2215/cjn.08710814" @default.
• W2252994773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4455215" @default.
• W2252994773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25979971" @default.
• W2252994773 hasPublicationYear "2015" @default.
• W2252994773 type Work @default.
• W2252994773 sameAs 2252994773 @default.
• W2252994773 citedByCount "52" @default.
• W2252994773 countsByYear W22529947732015 @default.
• W2252994773 countsByYear W22529947732016 @default.
• W2252994773 countsByYear W22529947732017 @default.
• W2252994773 countsByYear W22529947732018 @default.
• W2252994773 countsByYear W22529947732019 @default.
• W2252994773 countsByYear W22529947732020 @default.
• W2252994773 countsByYear W22529947732021 @default.
• W2252994773 countsByYear W22529947732022 @default.
• W2252994773 countsByYear W22529947732023 @default.
• W2252994773 crossrefType "journal-article" @default.
• W2252994773 hasAuthorship W2252994773A5016874418 @default.
• W2252994773 hasAuthorship W2252994773A5022620756 @default.
• W2252994773 hasAuthorship W2252994773A5030683638 @default.
• W2252994773 hasAuthorship W2252994773A5038631687 @default.
• W2252994773 hasAuthorship W2252994773A5046182499 @default.
• W2252994773 hasAuthorship W2252994773A5056261742 @default.
• W2252994773 hasAuthorship W2252994773A5064511107 @default.
• W2252994773 hasAuthorship W2252994773A5065873172 @default.
• W2252994773 hasAuthorship W2252994773A5067822524 @default.
• W2252994773 hasAuthorship W2252994773A5077167854 @default.
• W2252994773 hasAuthorship W2252994773A5077759641 @default.
• W2252994773 hasAuthorship W2252994773A5081469801 @default.
• W2252994773 hasAuthorship W2252994773A5084636437 @default.
• W2252994773 hasBestOaLocation W22529947731 @default.
• W2252994773 hasConcept C126322002 @default.
• W2252994773 hasConcept C156957248 @default.
• W2252994773 hasConcept C207103383 @default.
• W2252994773 hasConcept C2777630719 @default.
• W2252994773 hasConcept C2778720950 @default.
• W2252994773 hasConcept C2779015954 @default.
• W2252994773 hasConcept C2780303639 @default.
• W2252994773 hasConcept C2780882860 @default.
• W2252994773 hasConcept C2909675724 @default.
• W2252994773 hasConcept C2911091166 @default.
• W2252994773 hasConcept C44249647 @default.
• W2252994773 hasConcept C71924100 @default.
• W2252994773 hasConcept C72563966 @default.

• next